- Home
- GLNG vs RNA Comparison
GLNG vs RNA Comparison
Compare GLNG & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLNG
- RNA
- Stock Information
- Founded
- GLNG 1946
- RNA 2012
- Country
- GLNG Bermuda
- RNA United States
- Employees
- GLNG N/A
- RNA N/A
- Industry
- GLNG Marine Transportation
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- GLNG Consumer Discretionary
- RNA Health Care
- Exchange
- GLNG Nasdaq
- RNA Nasdaq
- Market Cap
- GLNG 4.1B
- RNA 3.4B
- IPO Year
- GLNG N/A
- RNA 2020
- Fundamental
- Price
- GLNG $41.16
- RNA $30.98
- Analyst Decision
- GLNG Strong Buy
- RNA Strong Buy
- Analyst Count
- GLNG 5
- RNA 12
- Target Price
- GLNG $48.70
- RNA $67.92
- AVG Volume (30 Days)
- GLNG 2.0M
- RNA 1.4M
- Earning Date
- GLNG 01-01-0001
- RNA 05-08-2025
- Dividend Yield
- GLNG 2.43%
- RNA N/A
- EPS Growth
- GLNG N/A
- RNA N/A
- EPS
- GLNG 0.03
- RNA N/A
- Revenue
- GLNG $257,915,000.00
- RNA $8,927,000.00
- Revenue This Year
- GLNG $70.72
- RNA N/A
- Revenue Next Year
- GLNG N/A
- RNA $148.12
- P/E Ratio
- GLNG $1,128.48
- RNA N/A
- Revenue Growth
- GLNG N/A
- RNA N/A
- 52 Week Low
- GLNG $25.33
- RNA $21.51
- 52 Week High
- GLNG $44.36
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- GLNG 58.21
- RNA 53.85
- Support Level
- GLNG $36.72
- RNA $30.00
- Resistance Level
- GLNG $42.42
- RNA $32.09
- Average True Range (ATR)
- GLNG 1.35
- RNA 1.79
- MACD
- GLNG 0.19
- RNA 0.13
- Stochastic Oscillator
- GLNG 77.89
- RNA 75.00
About GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.